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TT may be more informative than aPTT and HTI to provide
with guidance to carry out an urgent procedure or surgery
for patients receiving DE. However, TT is affected by a lot of
analytic variables that should be understood by laboratories.
Each laboratory should optimize its TT procedure according
to its combination coagulometer-reagent.
Results and Discussion
Objectives
Methods
Possibilities to monitor the intensity of dabigatran etexilate
(DE) treatment may be valuable before urgent
intervention. The Working Group on Perioperative
Haemostasis proposed that the drug plasma concentration
([]) should be less or equal to 30ng/mL. However, plasma
levels where it is safe to carry out an invasive procedure or
surgery have not been confirmed prospectively. In
addition, no biological test has been correlated with
bleeding risk. Literature showed heterogeneous data
regarding the arrest of DE depending on the renal function
and the haemorrhagic risk. In addition, physicians request
guidance for patients excluded from the clinical trials.
Consequently, there is still a need for a rapid and widely
available biological test.
Some authors make proposals based on activated Partial
Thromboplastin Time (aPTT), Hemoclot Thrombin
Inhibitor® (HTI) or Thrombin Time (TT).1,2 TT displayed
several advantages over aPTT. However, TT is affected by
numerous analytic variables.1
1. To determine the optimal [thrombin] with a variety of instruments and reagents
2. To assess the repeatability of TT at optimized conditions
3. To compare the sensitivity and linearity of TT at residual [dabigatran] (DA) with 
those of aPTT and HTI
4. To validate the fibrinogen reagent (with heparin inhibitor) for TT experiments
Dabigatran was spiked at increasing [ ] in pooled citrated normal human platelet-poor plasma (NPP). The following [DA] were prepared: 0, 5, 10, 20, 30,
40 and 50ng/ml.
Optimal [thrombin] determination.
- The optimal [thrombin] was defined with 2 reagents: bovine thrombin (HemosIL® TT) and human thrombin (STA®-Thrombin) on 4 instruments: STA-R
Evolution®, ACL-TOP® , CS2000i® and KC10®.
- TT higher than Tmax is not informative for the physician. Thus, the optimized [thrombin] was defined as the maximum [thrombin] giving, in a
reproducible way, a TT at 50ng/ml lower than Tmax and a TT at 0ng/ml higher than the minimum TT. The Tmax was set arbitrarily at 120 sec.
- The repeatability of optimized TT was assessed by running aliquots of NPP spiked with all [DA] on 10 consecutive days
- TT (1.5 NIH/ml, STA®-Thrombin), aPTT with SynthasIL® and STA®-C.K.Prest, and HTI were also determined within 1 hour on STA-R® on replicates of
all NPP solutions.
- STA®- Fibrinogen-5 was diluted to the optimized [thrombin] (1.5 NIH/ml) on STA-R® and used as a thrombin reagent.
The thrombin origin is a more important variable in comparison to the type of coagulometer. At
[DA] of 30ng/ml and [thrombin] of 1.5 NIH/ml, the STA®-TT ranges from 56 sec to 74 sec
according to the instrument, whereas on a same instrument, the TT varied of minimum 43 sec,
depending on the thrombin origin.
The optimized [thrombin] are the following :
a) STA-R®, STA®-Thrombin : 1.5 NIH/ml,
b) STA-R®, HemosIL® TT : 3.8 NIH/ml,
c) ACLTOP®, STA®-Thrombin 3.8 NIH/ml,
d) ACLTOP®, HemosIL® TT 5.0 NIH/ml,
e) KC10®, STA®-Thrombin 1.5 NIH/ml,
f) KC10®, HemosIL® TT 5.0 NIH/ml,
g) CS2000i®, STA®-Thrombin 1.4 NIH/ml,
h) CS2000i®, HemosIL® TT 3.8 NIH/ml.
Except for STA®-Thrombin on STA-R®, the [optimized] is not the one recommended by the
manufacturer. Figure 1 shows the results of optimized TT according to thrombin origin and
coagulometer.
Repeatability experiments showed that variability increased with the [DA] (i.e. STA®-Thrombin
(STA-R®): coefficient of variation: 8.0% and 28.9% for 0ng/ml and 50ng/ml, respectively) and that
the variability depends on the coagulometer and the reagent.
Comparison of sensitivity and linearity of TT, aPTT and HTI are presented in Table 1. APTT is not
sensitive enough in low [DA], whatever the reagent, whereas HTI is not suitable in [DA] lower
than 50ng/ml.
TT performed with fibrinogen reagent shows longer times in comparison to thrombin reagent
(>120 sec vs 109 sec at 30ng/ml DA).
[Dabigatran] (ng/ml) TT (sec)
aPTT
(sec, SynthasIL®)
aPTT 
(sec, STA®-C.K.Prest)
HTI 
(ng/ml)
0 17.9 30.3 31.2 0.0
5 22.0 31.2 33.1 0.0
10 31.5 32.4 34.5 0.0
20 59.3 34.9 38.6 7.2
30 82.9 36.0 39.6 10.3
40 100.9 38.0 42.8 21.3
50 120.0 39.3 44.2 27.4
Table 1: Clotting time of optimized thrombin time, aPTT with
different reagents and comparison with HTI
Figure 1: Comparison of the clotting
time obtained with the different
platform-reagent combinations
